Partial
Needs Review
Patient Risk:
Moderate
Summary
Several claims align with the label (generic name, benzodiazepine class, mechanism binding to GABA-A, labeled indications for GAD and PD, and dependence/withdrawal guidance). However, multiple claims are not supported by the provided prescribing-information excerpts (notably several “common side effects” and tolerance), and two indication-related claims are contradicted (anxiety associated with depression is not an approved indication).
Category Scores
Accurate Statements
Alprazolam is the generic name for Xanax.
11 DESCRIPTION (XANAX contains alprazolam)
Alprazolam is a medication within the benzodiazepine class.
11 DESCRIPTION; 12.1 Mechanism of Action (Alprazolam is a 1,4 benzodiazepine)
Xanax is approved for acute treatment of generalized anxiety disorder (GAD) in adults.
1 INDICATIONS AND USAGE (acute treatment of generalized anxiety disorder (GAD) in adults)
Xanax is approved for treatment of panic disorder (PD), with or without agoraphobia, in adults.
1 INDICATIONS AND USAGE (treatment of panic disorder (PD), with or without agoraphobia in adults)
Like other benzodiazepines, Xanax carries risks of dependence and withdrawal.
5 WARNINGS AND PRECAUTIONS (Dependence and Withdrawal Reactions described elsewhere); 17 Patient Counseling Information (withdrawal reactions; abrupt discontinuation/rapid dosage reduction)
Withdrawal symptoms can occur if Xanax is stopped abruptly.
17 PATIENT COUNSELING INFORMATION (abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions)
Alprazolam exerts its effect by binding to the benzodiazepine site of GABA-A receptors in the brain and enhances GABA-mediated synaptic inhibition.
12.1 Mechanism of Action (binding to benzodiazepine site of GABA-A receptors; enhances GABA-mediated synaptic inhibition)
Unsupported Statements
Alprazolam was developed by Upjohn, which is now part of Pfizer.
Not supported by the provided label excerpts.
Alprazolam was first approved by the U.S. FDA in October 1981.
Not supported by the provided label excerpts.
Alprazolam is primarily prescribed for the treatment of anxiety disorders.
Only GAD and PD are listed in the provided indications; the broader “anxiety disorders” wording is not fully supported as stated.
Xanax functions by increasing the activity of gamma-aminobutyric acid (GABA) in the brain.
Label supports GABA-mediated synaptic inhibition enhancement via GABA-A receptor binding, but the specific phrasing “increasing the activity of GABA” is not directly stated in the provided excerpts.
Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that calms down nerve activity.
No label support in the provided excerpts.
By enhancing GABA's effects, alprazolam produces a sedative and anxiolytic (anxiety-reducing) effect.
Label provides mechanism and indicates use for GAD/PD, but the specific “sedative and anxiolytic effect” phrasing is not explicitly stated in the provided excerpts.
Common side effects of Xanax can include drowsiness.
No adverse-reaction statements supporting drowsiness in the provided label excerpts (6 ADVERSE REACTIONS section excerpt does not list specific common effects).
Common side effects of Xanax can include dizziness.
Not supported by the provided label excerpts.
Common side effects of Xanax can include lightheadedness.
Not supported by the provided label excerpts.
Common side effects of Xanax can include impaired coordination.
Not supported by the provided label excerpts.
Xanax should be used exactly as prescribed and under supervision of a healthcare professional due to its potential for misuse and dependence.
Label excerpts discuss abuse/misuse/addiction and dependence/withdrawal, but do not explicitly contain the exact phrasing “exactly as prescribed” and “under supervision” in a single supported instruction.
Long-term use of Xanax can lead to tolerance, where higher doses are needed to achieve the same effect.
Tolerance is not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Alprazolam is primarily prescribed for the treatment of anxiety associated with depression.
Label Reference
1 INDICATIONS AND USAGE (only acute treatment of GAD in adults and treatment of PD, with or without agoraphobia in adults are listed).
Low
AI Statement
Xanax is approved for the treatment of anxiety or tension associated with the symptoms of depression.
Label Reference
1 INDICATIONS AND USAGE (only acute treatment of GAD in adults and treatment of PD, with or without agoraphobia in adults are listed).
Important Omissions
Specific labeled dosage and administration instructions (e.g., dosing regimens, titration, maximum doses) were not assessed because no dosage/administration claims were provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary safety-relevant label adherence (dependence/withdrawal risks) is supported, but multiple “common side effects” and tolerance claims are not label-supported in the provided excerpts, and incorrect indication claims (anxiety/tension associated with depression) directly conflict with labeled indications.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Review
Primary Issue
Unlabeled/unsupported content (common side effects and tolerance) plus contradicted indication wording (anxiety/tension associated with depression not listed in labeled indications).
Suggested Improvement
Limit indication statements to the labeled indications (acute treatment of GAD in adults; PD with or without agoraphobia in adults) and remove or re-phrase side-effect and tolerance claims unless supported by the provided ADVERSE REACTIONS section text.